Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Lucira Health, Inc. (LHDX) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Disclosure Statement for Chapter 11 Plan of Liquidation for Lucira Health, Inc",
"Chapter 11 Plan of Liquidation for Lucira Health, Inc"
04/24/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
04/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Monthly Operating Report, for the period covering February 1, 2023 through February 28, 2023, filed with the United States Bankruptcy Court for the District of Delaware",
"Monthly Operating Report, for the period covering February 1, 2023 through February 28, 2023, filed with the United States Bankruptcy Court for the District of Delaware"
02/27/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"LUCIRA HEALTH ANNOUNCES FDA AUTHORIZATION OF FIRST & ONLY AT-HOME COMBINATION COVID-19 & FLU TEST AND COMMENTS ON CHAPTER 11 BANKRUPTCY FILING"
02/22/2023 8-K Bankruptcy or Receivership, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer...
Docs: "Lucira Health to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process"
01/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/28/2022 8-K Quarterly results
12/19/2022 8-K Quarterly results
12/15/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/01/2022 8-K Quarterly results
10/26/2022 8-K Quarterly results
09/22/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/15/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/14/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
Docs: "Lucira Health Announces Fourth Quarter and Full Year 2021 Results and Reaffirms 2022 Financial Outlook EMERYVILLE, Calif. - March 10, 2022 - Lucira Health, Inc. , a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights"
02/08/2022 8-K Quarterly results
01/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Lucira Health Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021 and Provides Business Update EMERYVILLE, CA, January 10, 2022 — Lucira Health, Inc. , a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced preliminary revenue results for the fourth quarter and full year 2021. Preliminary, unaudited revenue for the fourth quarter 2021 is expected to be between $58 million and $60 million, reflecting growth of approximately 300% over the unaudited third quarter of 2021. Preliminary unaudited revenue for full year 2021, the first year of commercialization, is expected to be between $90 million and $92 million. Based on sales pipeline visibility and manufacturing capacit..."
12/29/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Lucira Health and Co-Defend/Co-Protect Announce Expanded Partnership for 2022"
12/23/2021 8-K Regulation FD Disclosure  Interactive Data
12/21/2021 8-K Appointed a new director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
10/08/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "LUCIRA ™ HEALTH Provides Statement on Copan's Recall of its FLOQSwabs EMERYVILLE, CA, October 8, 2021 - Lucira Health, Inc. , a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today commented on the recent recall of the FLOQSwabs by supply partner Copan Italia SPA, or Copan. Copan, who supplies FLOQSwabs included in the LUCIRA COVID-19 All-In-One Test Kit and LUCIRA CHECK IT COVID-19 Test Kit, collectively the Test Kits, announced a recall of its FLOQSwabs. According to Lucira's records, Test Kits containing the recalled Copan swabs were distributed from April 22, 2021 through September 22, 2021. Lucira estimates expenses related to the recalled Copan swabs to be between $75,000 and $85,000 and inten..."
09/20/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, between Tony Allen and Lucira Health, Inc"
08/27/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
07/27/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 21, 2021 Lucira Health, Inc. Delaware 001-39976 27-2491037 1412 62nd Street Emeryville, California 94608 Registrant's telephone number, including area code: 350-8071 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communica..."
07/16/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 16, 2021 Lucira Health, Inc. Delaware 001-39976 27-2491037 1412 62nd Street Emeryville, California 94608 Registrant's telephone number, including area code: 350-8071 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communica..."
05/28/2021 8-K Quarterly results
05/27/2021 8-K Quarterly results
05/18/2021 8-K Quarterly results
04/13/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy